Attorneys for plaintiffs in a Puerto Rico class action against Novartis,manufacturer of Ritalin (methylphenidate), the American Psychiatric Association and Children and Adults with Attention Deficit/Hyperactivity Disorder, have notified the court that they are dismissing their case against the defendants. Their lawsuit, served in February 2001, had claimed that the defendants conspired to promote the diagnosis of ADHD.
The plaintiffs' decision follows a similar move by such claimants in Florida and dismissed by the courts in lawsuits filed in California (Marketletter March 19) and Texas (Marketletter May 28).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze